Amicus Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Amicus Therapeutics is Brad Campbell, benoemd in Jan2015, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.20M, bestaande uit 8.5% salaris en 91.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde $ 8.57M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 6.3 jaar.

Belangrijke informatie

Brad Campbell

Algemeen directeur

US$8.2m

Totale compensatie

Percentage CEO-salaris	8.5%
Dienstverband CEO	9.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	7.7yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Brad Campbell's beloning veranderd ten opzichte van Amicus Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$105m
Jun 30 2024	n/a	n/a	-US$120m
Mar 31 2024	n/a	n/a	-US$147m
Dec 31 2023	US$8m	US$699k	-US$152m
Sep 30 2023	n/a	n/a	-US$174m
Jun 30 2023	n/a	n/a	-US$185m
Mar 31 2023	n/a	n/a	-US$204m
Dec 31 2022	US$9m	US$591k	-US$237m
Sep 30 2022	n/a	n/a	-US$264m
Jun 30 2022	n/a	n/a	-US$281m
Mar 31 2022	n/a	n/a	-US$270m
Dec 31 2021	US$5m	US$551k	-US$250m
Sep 30 2021	n/a	n/a	-US$239m
Jun 30 2021	n/a	n/a	-US$252m
Mar 31 2021	n/a	n/a	-US$254m
Dec 31 2020	US$5m	US$516k	-US$277m
Sep 30 2020	n/a	n/a	-US$295m
Jun 30 2020	n/a	n/a	-US$293m
Mar 31 2020	n/a	n/a	-US$325m
Dec 31 2019	US$4m	US$501k	-US$356m
Sep 30 2019	n/a	n/a	-US$345m
Jun 30 2019	n/a	n/a	-US$442m
Mar 31 2019	n/a	n/a	-US$419m
Dec 31 2018	US$3m	US$468k	-US$349m
Sep 30 2018	n/a	n/a	-US$340m
Jun 30 2018	n/a	n/a	-US$293m
Mar 31 2018	n/a	n/a	-US$279m
Dec 31 2017	US$2m	US$450k	-US$284m

Compensatie versus markt: De totale vergoeding ($USD 8.20M ) Brad } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 2.68M ).

Compensatie versus inkomsten: De vergoeding van Brad is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Brad Campbell (48 yo)

9.8yrs

Tenure

US$8,202,366

Compensatie

Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bradley Campbell	CEO, President & Director	9.8yrs	US$8.20m	0.30% $ 8.6m
Simon Nicolas Harford	Chief Financial Officer	1.3yrs	US$3.27m	0.0048% $ 137.4k
Ellen Rosenberg	Chief Legal Officer & Corporate Secretary	8.8yrs	US$4.08m	0.064% $ 1.8m
David Clark	Chief People Officer	6.1yrs	US$3.21m	0.046% $ 1.3m
Jeffrey Castelli	Chief Development Officer	no data	US$3.67m	0.080% $ 2.3m
Samantha Prout	Chief Accounting Officer & Controller	6.7yrs	geen gegevens	0.025% $ 714.1k
Jill Weimer	Chief Science Officer	no data	geen gegevens	geen gegevens
Andrew Faughnan	Senior Director of Investor Relations	no data	geen gegevens	geen gegevens
Patrik Florencio	Global Chief Compliance & Risk Officer	9.3yrs	geen gegevens	geen gegevens
Diana Moore	Head of Global Corporate Communications	no data	geen gegevens	geen gegevens
Jayne Gershkowitz	Chief Patient Advocate	9.2yrs	geen gegevens	geen gegevens
Julie Yu	Chief Program Officer	4.5yrs	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0HF9 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bradley Campbell	CEO, President & Director	6.4yrs	US$8.20m	0.30% $ 8.6m
Burke Whitman	Independent Director	5.4yrs	US$391.25k	0.026% $ 751.1k
Michael Kelly	Independent Director	3.9yrs	US$391.25k	0.0098% $ 284.0k
Glenn Sblendorio	Independent Director	18.4yrs	US$407.07k	0.025% $ 724.5k
Margaret McGlynn	Independent Director	15.1yrs	US$401.25k	0.017% $ 489.8k
Michael Raab	Chairman & Lead Independent Director	20.8yrs	US$426.25k	0.025% $ 724.5k
Eiry Roberts	Independent Director	3.4yrs	US$390.00k	0.0080% $ 232.4k
Lynn Bleil	Independent Director	6.2yrs	US$397.50k	0.024% $ 706.0k

6.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0HF9 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Amicus Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Amicus Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Amicus Therapeutics Announces Executive Changes

Amicus Therapeutics, Inc. Announces Chief Financial Officer Changes

Amicus Therapeutics, Inc. Announces Retirement of Daphne Quimi as Chief Financial Officer

Amicus Therapeutics, Inc. Appoints Samantha Prout as Chief Accounting Officer and Controller

Recent updates

Third quarter 2024 earnings released: US$0.022 loss per share (vs US$0.073 loss in 3Q 2023)

Amicus Therapeutics, Inc. Raises Earnings Guidance for the Year 2024

Amicus Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.052 loss per share (vs US$0.15 loss in 2Q 2023)

Amicus Therapeutics, Inc. Raises Earnings Guidance for the Year 2024

Amicus Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2023)

Amicus Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Amicus Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Forecast breakeven date pushed back to 2025

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$0.51 loss per share (vs US$0.82 loss in FY 2022)

Amicus Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Forecast to breakeven in 2024

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Insufficient new directors

Amicus Therapeutics Announces Executive Changes

Forecast to breakeven in 2024

Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.12 loss in 3Q 2022)

Amicus Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Amicus Therapeutics, Inc. announced that it has received $29.999985 million in funding

New minor risk - Share price stability

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

New Paradigm Therapeutics, Inc. acquired worldwide rights of SD-101 from Amicus Therapeutics, Inc. (NasdaqGM:FOLD).

Amicus Therapeutics, Inc. Announces Chief Financial Officer Changes

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.21 loss in 2Q 2022)

Amicus Therapeutics, Inc. Announces Retirement of Daphne Quimi as Chief Financial Officer

New minor risk - Share price stability

Amicus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Amicus Therapeutics, Inc. Appoints Samantha Prout as Chief Accounting Officer and Controller

Amicus Therapeutics Inc. Announces Approval and Launch of New Pompe Disease Therapy in the European Union

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$0.82 loss per share (vs US$0.92 loss in FY 2021)

Amicus Therapeutics, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2023

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.19 loss in 3Q 2021)

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2022

Amicus Therapeutics, Inc. Announces U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

Amicus Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Executive Chairman recently sold US$112k worth of stock

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2021)

Amicus Therapeutics, Inc. Provides Guidance for 2022

Amicus Therapeutics, Inc. Appoints Bradley L. Campbell as Chief Executive Officer

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.25 loss in 1Q 2021)

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full Year of 2022

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Amicus Therapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Amicus Therapeutics, Inc. Provides Unaudited Revenue Guidance for the Year 2021 and 2022

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.25 loss in 3Q 2020)

High number of new directors

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2020)

Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease

Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA

Independent Director recently bought US$250k worth of stock

First quarter 2021 earnings released: US$0.25 loss per share (vs US$0.35 loss in 1Q 2020)

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2021

Amicus Therapeutics, Inc. Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease

Full year 2020 earnings released: US$1.07 loss per share (vs US$1.48 loss in FY 2019)

Revenue beats expectations

Amicus Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 01, 2021

Amicus Therapeutics, Inc. Announces Topline Results of its Phase 3 PROPEL Pivotal Trial for AT-GAA